PSH.F - Sernova Corp.
| Previous Close | 0.5700 |
| Open | 0.5545 |
| Bid | 0.5710 x 1000000 |
| Ask | 0.5945 x 1000000 |
| Day's Range | 0.5545 - 0.5545 |
| 52 Week Range | 0.4892 - 1.1690 |
| Volume | |
| Avg. Volume | 2,718 |
| Market Cap | 168.198M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireSernova Announces Executive Alignment and Appoints New Board Chair
LONDON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive leadership review conducted by its Board of Directors (the “Board”). Following the recent 2023 Annual General Meeting of Shareholders (the “AGM”), the Sernova Board welcomed Mr. Brett Whalen, Dr. Steven Sangha and Mr. Bertram von Plettenberg as newly elected Directors. The
- GlobeNewswire
Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells. “Sernova has developed a novel cell therapy approach for the potential treatment of insulin-dependent diabetes, hyp
CNW GroupConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholders
The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") wishes to thank all shareholders for their participation in electing the next Board of Directors.
- GlobeNewswire
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human isletsThe ILCs are cryopreserved during manufacturing, enabling storage of mass volumes and cost efficient on-demand worldwide delivery as requiredResults from a type 1 diabetes (T1D) preclinical mo
- Baystreet
Stocks in play: Sernova Corp.
Reminds shareholders to vote the WHITE management proxy in advance of the proxy voting deadline on Tuesday ...
- GlobeNewswire
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC., Recommend Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
Following Institutional Shareholder Services’ positive recommendations, Glass Lewis is the second independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.Glass Lewis does not believe Sernova’s dissident shareholders have compiled a sufficiently compelling case to warrant investor support and refers to their arguments as “incomplete”.Shareholders who have questions or need assistance with voti
CNW GroupConcerned Shareholders of Sernova Corp. Stand by their Statements
The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") maintains that the decrease in share valuation, lack of investor updates and progress relating to clinical studies, deficiencies relating to business development and partnerships, unjustified compensation as well as corporate governance issues have not been addressed by the current board of directors, nor by the current management te
- GlobeNewswire
UPDATE -- Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.ISS notes the dissidents failed to present a detailed explanation of their case and there does not seem to be a compelling case that change at Sernova is warranted at this time.Shareholders who have questions or need assistance with voting their shares should contact Sernova Corp.’s strategic advisor and proxy solicitation agent L
- GlobeNewswire
Institutional Shareholder Services Inc. Recommends Senova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.ISS notes the dissidents failed to present a detailed explanation of their case and there does not seem to be a compelling case that change at Sernova is warranted at this time.Shareholders who have questions or need assistance with voting their shares should contact Sernova Corp.’s strategic advisor and proxy solicitation agent L
- GlobeNewswire
Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Barcelona in Barcelona, Spain and livestreamed globally. Panel: Navigating CGTx Development in 2023 Date: Wednesday, April 12, 2023 Time: 4:
- GlobeNewswire
Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates
The dissident director nominees declined to follow proper protocol to participate in Sernova’s board renewal process and instead are imposing themselves on the Company through a costly and disruptive proxy battleManagement and the Board have placed Sernova in a position to bring value to shareholders and in a challenging time for companies in the biotech sector, Sernova’s share price is up 17% year-to-date compared to an 8% decline in the benchmark Nasdaq XBI biotech index over the same periodSh
CNW GroupConcerned Shareholders of Sernova Corp. Nominate Two Highly Qualified Directors to the Board
A group of longstanding shareholders of Sernova Corp (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) ("Sernova" or the "Company") who currently own approximately 12% of the Company's shares have concerns regarding the performance of Sernova's Board (the "Concerned Shareholders"). Sernova's Board needs new voices. They are nominating two highly qualified individuals to bring independent shareholder representation to the Board and to address some significant issues that have impeded the Company's ability
CNW GroupAdvance Notice Filed with Sernova Corp. for the Nomination of Two Director Nominees
Betty Anne Millar has filed a notice (the "Notice") with Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) ("Sernova" or the "Company") for the nomination of two highly experienced independent directors to be elected to the board of Sernova at the annual general meeting to be held on April 27, 2023 (the "Meeting"). Mrs. Millar, together with joint actors (the "Group of Shareholders"), holds directly and indirectly an aggregate of 35,789,615 shares, representing approximately 12% of the Company's issued an
- GlobeNewswire
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023
LONDON, Ontario, March 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions, to be held from June 23-26, 2023, in San Diego, CA. It will also be published on the journal Diabetes® website. Abstract: #240-ORTitle: Islet Allotransplantation into
- GlobeNewswire
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
First pre-clinical data presentation of Sernova’s Cell Pouch with Evotec’s iPSC derived islet-like cluster technology for type 1 diabetes (T1D)LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant Association (IPITA) / Harvard Stem Cell Institute (HSCI) / Ju
- GlobeNewswire
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Third patient now implanted with higher capacity, 10-chamber Cell PouchCompany anticipates first interim data from second cohort in Q4 2023 LONDON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 clinical trial for the treatment of type 1 diabetes (“T1D”) and hypoglycemia unawareness (the “T1D St
- GlobeNewswire
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Sernova provides warrant updateLONDON, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, taking place March 13-15, 2023. Company management will also be participating in one-on-one investor meetings at the conferences. 35th
- GlobeNewswire
Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid glandSernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy for hypothyroidism LONDON, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced advanceme
- GlobeNewswire
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemiaiPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluationT1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated co
- GlobeNewswire
Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointmentLONDON, Ontario, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its p
- GlobeNewswire
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into the enhanced 10-channel Cell Pouch is anticipated in early 2023Company continues to anticipate first interim safety/efficacy data from second cohort in 2023 LONDON, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced to
- GlobeNewswire
Sernova to Participate in the Stifel Healthcare Conference
LONDON, Ontario, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on November 15-16, 2022. Company management will also be participating in one-on-one investor meetings at the conference. Stifel Healthcare Conference Date:9:45AM, November 15, 2022Presenter:Dr. Philip Toleikis, Pres
- GlobeNewswire
Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
Sernova plans to begin enrollment of second cohort in the coming weeks and implant multiple patients with the enhanced capacity 10-channel Cell Pouch before the end of 2022Positive interim results from patients in the first cohort informed the islet dose and density threshold optimizations for the second cohortExpedited enrollment is anticipated with Sernova’s engagement of an experienced clinical trial patient recruitment agency and the Company expects to report interim data in 2023Results from
- GlobeNewswire
Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference
LONDON, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced it will be presenting at the upcoming Roth Inaugural Healthcare Opportunities Conference being held in-person in New York, NY on October 6, 2022. Company management will also be participating in one-on-one investor meetings at the conference. Roth Inaugural Healthcare Opportunities Conference Date:Thursda
- GlobeNewswire
Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022
Additional $3.5M of capital raised from exercise of expiring warrantsLONDON, Ontario, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE / XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced that all remaining share purchase warrants related to the 2020 private placement, expiring on September 22, 2022, have been exercised with additional proceeds of $3.5M received since the Company’s last update on September 1, 2022. Capi